Noida Chronicle

Centronuclear Myopathy Overview

Centronuclear Myopathy: Centronuclear myopathies are a group of muscle diseases that are considered part of a larger family of muscle diseases known as congenital myopathies, a group of genetic muscle disorder that are evident at or around the time of birth.

“Centronuclear Myopathy Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Centronuclear Myopathy Market.

The Centronuclear Myopathy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Centronuclear Myopathy Pipeline Report:

• Companies across the globe are diligently working toward developing novel Centronuclear Myopathy treatment therapies with a considerable amount of success over the years. Centronuclear Myopathy Key players such as – ARMGO Pharma, Dynacure, Astellas Gene Therapies, and others, are developing therapies for the Centronuclear Myopathy treatment 
• Centronuclear Myopathy Emerging therapies such as – ARM210, DYN101, AT-132, and others are expected to have a significant impact on the Centronuclear Myopathy market in the coming years.   
• In October 2021, Dynacure initiated a Phase 1/2, Multicenter, Open-label, Dose-confirmation Trial to Evaluate the Safety and Preliminary Efficacy of DYN101 in Participants 2 to 17 Years of Age With Centronuclear Myopathy Caused by Mutations in MTM1 or DNM2
• In November 2021, Dynacure, announced that Dynacure and Nippon Shinyaku Co., Ltd. have entered a long-term strategic development and commercialization agreement. Nippon Shinyaku has obtained an exclusive option to acquire development and commercial rights from Dynacure to develop DYN101
• In November 2021, Dynacure, announced that Dynacure and Nippon Shinyaku Co., Ltd. have entered a long-term strategic development and commercialization agreement. Nippon Shinyaku has obtained an exclusive option to acquire development and commercial rights from Dynacure to develop DYN101
• In January 2020, Dynacure initiated a Phase 1/2 Trial on the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Exploratory Efficacy of DYN101 in Patients ≥ 16 Years of Age With Centronuclear Myopathies Caused by Mutations in DNM2 or MTM1.This trial will assess the safety, tolerability, PK and PD/preliminary efficacy of a new medicine called DYN101 in patients ≥ 16 years of age with CNM caused by mutations in DNM2 or MTM1

Route of Administration

Centronuclear Myopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types, such as

• Oligonucleotide
• Peptide
• Small molecule

Centronuclear Myopathy Pipeline Therapeutics Assessment

• Centronuclear Myopathy Assessment by Product Type
• Centronuclear Myopathy By Stage and Product Type
• Centronuclear Myopathy Assessment by Route of Administration
• Centronuclear Myopathy By Stage and Route of Administration
• Centronuclear Myopathy Assessment by Molecule Type
• Centronuclear Myopathy by Stage and Molecule Type

DelveInsight’s Centronuclear Myopathy Report covers around 5+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Some of the key companies in the Centronuclear Myopathy Therapeutics Market include:

Key companies developing therapies for Centronuclear Myopathy are – Audentes Therapeutics, Ionis Pharmaceuticals, Inc, Dynacure, Valerion Therapeutics, Biophytis, ARMGO Pharma Inc, Stealth BioTherapeutics Inc, Novartis AG, CENTOGENE AG, Sanofi, KalVista Pharmaceuticals, Pfizer Inc., GlaxoSmithKline plc., AstraZeneca, Medtronic, Lilly, F. Hoffmann-La Roche Ltd, Amgen Inc., Johnson & Johnson Private Limited, ., and AbbVie Inc., and others.

Emerging Centronuclear Myopathy Drugs Under Different Phases of Clinical Development Include:

• ARM210: ARMGO Pharma
• DYN101: Dynacure
• AT-132: Astellas Gene Therapies

Get a Free Sample PDF Report to know more about Centronuclear Myopathy Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/centronuclear-myopathy-cnm-pipeline-insight

Centronuclear Myopathy Pipeline Analysis:

The Centronuclear Myopathy pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Centronuclear Myopathy with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Centronuclear Myopathy Treatment.
• Centronuclear Myopathy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Centronuclear Myopathy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Centronuclear Myopathy market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Centronuclear Myopathy product details are provided in the report. Download the Centronuclear Myopathy pipeline report to learn more about the emerging Centronuclear Myopathy therapies

Centronuclear Myopathy Pipeline Market Drivers

• Increase in the number of patients suffering from Centronuclear Myopathy
• Increasing awareness about the disease

Centronuclear Myopathy Pipeline Market Barriers

• Higher cost of research and development

Scope of Centronuclear Myopathy Pipeline Drug Insight    

• Coverage: Global
• Key Centronuclear Myopathy Companies: ARMGO Pharma, Dynacure, Astellas Gene Therapies, and others
• Key Centronuclear Myopathy Therapies: ARM210, DYN101, AT-132, and others
• Centronuclear Myopathy Therapeutic Assessment: Centronuclear Myopathy current marketed and Centronuclear Myopathy emerging therapies
• Centronuclear Myopathy Market Dynamics: Centronuclear Myopathy market drivers and Centronuclear Myopathy market barriers 

Request for Sample PDF Report for Centronuclear Myopathy Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report to know more about Centronuclear Myopathy drugs and therapies

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting